MedTrace Logo

Non-intrusive Detection of Temporary Neurologic Impairment by Opioids

NCT05489601 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 17

Last updated 2022-08-05

No results posted yet for this study

Summary

The investigators aim to prove the feasibility of a non-invasive means to identify temporary neurological impairment resulting from the use of a commonly prescribed opioid by identifying an oculomotor biosignature associated with temporary neurologic impairment in pain-free opioid-naïve subjects, and to initiate the development of such a signature. The investigators also sought to establish the presence of a dose-dependent biosignature for opioid impairment.

Conditions

  • Neurologic Impairment by Opioids

Interventions

DRUG

Oxycodone

Oxycodone in 5mg increments up to a maximum of 10mg

Sponsors & Collaborators

  • Zxerex Corporation

    lead INDUSTRY

Eligibility

Min Age
21 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-28
Primary Completion
2022-03-29
Completion
2022-03-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05489601 on ClinicalTrials.gov